China Medical System Holdings Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CHSYF research report →
Companywww.cms.net.cn
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.
- CEO
- Kong Lam
- IPO
- 2013
- Employees
- 6,141
- HQ
- North Point, HK
Price Chart
Valuation
- Market Cap
- $3.27B
- P/E
- 15.48
- P/S
- 2.83
- P/B
- 1.32
- EV/EBITDA
- 11.63
- Div Yield
- 2.97%
Profitability
- Gross Margin
- 71.50%
- Op Margin
- 19.22%
- Net Margin
- 18.13%
- ROE
- 8.65%
- ROIC
- 5.89%
Growth & Income
- Revenue
- $8.00B · 7.11%
- Net Income
- $1.45B · -10.45%
- EPS
- $0.60 · -10.45%
- Op Income
- $1.54B
- FCF YoY
- -69.97%
Performance & Tape
- 52W High
- $1.64
- 52W Low
- $0.93
- 50D MA
- $1.35
- 200D MA
- $1.35
- Beta
- 1.12
- Avg Volume
- 96.12
Get TickerSpark's AI analysis on CHSYF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CHSYF Coverage
We haven't published any research on CHSYF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CHSYF Report →